The Complement System Is Activated in a Biphasic Pattern After Coronary Artery Bypass Grafting

Annals of Thoracic Surgery

Volumn 89, Issue 3, 2010, Pages 710-716

  Hoedemaekers, Cornelia ^a   van Deuren, Marcel ^a   Sprong, Tom ^a   Pickkers, Peter ^a   Mollnes, Tom Eirik ^b   Klasen, Ina ^a   van der Hoeven, Johannes ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; INTERLEUKIN 10; INTERLEUKIN 6; MANNOSE BINDING LECTIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; COMPLEMENT ACTIVATION; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 76749093139     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.11.049     Document Type: Article

References (29)

1. Nilsson B., Ekdahl K.N., Mollnes T.E., and Lambris J.D. The role of complement in biomaterial-induced inflammation. Mol Immunol 44 (2007) 82-94
2. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion 16 (2001) 353-360
3. Bruins P., te Velthuis H., Yazdanbakhsh A.P., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
4. Bruins P., te Velthuis H., Eerenberg-Belmer A.J., et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 84 (2000) 237-243
5. Kirklin J.K., Westaby S., Blackstone E.H., Kirklin J.W., Chenoweth D.E., and Pacifico A.D. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86 (1983) 845-857
6. Seghaye M.C., Duchateau J., Grabitz R.G., et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg 106 (1993) 978-987
7. Bilgin Y.M., Brand A., Berger S.P., Daha M.R., and Roos A. Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac surgery: effects of blood transfusions. Transfusion 48 (2008) 601-608
8. Levy J.H., and Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 75 Suppl (2003) S715-S720
9. Carrier M., Menasche P., Levy J.H., et al. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery. J Thorac Cardiovasc Surg 131 (2006) 352-356
10. Fattouch K., Bianco G., Speziale G., et al. Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 32 (2007) 326-332
11. Shernan S.K., Fitch J.C., Nussmeier N.A., et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77 (2004) 942-949
12. Testa L., Van Gaal W.J., Bhindi R., et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 136 (2008) 884-893
13. Verrier E.D., Shernan S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291 (2004) 2319-2327
14. Hoedemaekers C.W., Pickkers P., Netea M.G., van Deuren M., and Van der Hoeven J.G. Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass grafting: a randomized controlled trial [ISRCTN95608630]. Crit Care 9 (2005) R790-R797
15. Mollnes T.E., Lea T., Froland S.S., and Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22 (1985) 197-202
16. Garred P., Mollnes T.E., and Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 27 (1988) 329-335
17. Fure H., Nielsen E.W., Hack C.E., and Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand J Immunol 46 (1997) 553-557
18. Mollnes T.E., Brekke O.L., Fung M., et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
19. Wolbink G.J., Bollen J., Baars J.W., et al. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 163 (1993) 67-76
20. Sprong T., Roos D., Weemaes C., et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 107 (2006) 4865-4870
21. Gershov D., Kim S., Brot N., and Elkon K.B. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
22. Claus D.R., Siegel J., Petras K., Osmand A.P., and Gewurz H. Interactions of C-reactive protein with the first component of human complement. J Immunol 119 (1977) 187-192
23. Volanakis J.E., and Kaplan M.H. Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 113 (1974) 9-17
24. Jarva H., Jokiranta T.S., Hellwage J., Zipfel P.F., and Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 163 (1999) 3957-3962
25. Sjoberg A.P., Trouw L.A., McGrath F.D., Hack C.E., and Blom A.M. Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol 176 (2006) 7612-7620
26. Mold C., and Gewurz H. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. J Immunol 127 (1981) 2089-2092
27. Mold C., Kingzette M., and Gewurz H. C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b. J Immunol 133 (1984) 882-885
28. Franke A., Lante W., Fackeldey V., et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know?. Eur J Cardiothorac Surg 28 (2005) 569-575
29. van den Goor J., Nieuwland R., van den Brink A., et al. Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response. Eur J Cardiothorac Surg 26 (2004) 926-931